首页 > 最新文献

JAMA dermatology最新文献

英文 中文
Successful Treatment of Recalcitrant Chloracne With Adalimumab in an Older Man. 阿达木单抗成功治疗一名老年人顽固性氯痤疮
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.4263
Poonam Saini, Nitish Kumar, Naveen Kumar Kansal, Ashok Singh, Elumalai Gnanamani, Naveen Kumar, Riti Bhatia
{"title":"Successful Treatment of Recalcitrant Chloracne With Adalimumab in an Older Man.","authors":"Poonam Saini, Nitish Kumar, Naveen Kumar Kansal, Ashok Singh, Elumalai Gnanamani, Naveen Kumar, Riti Bhatia","doi":"10.1001/jamadermatol.2024.4263","DOIUrl":"10.1001/jamadermatol.2024.4263","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1367-1369"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and Patient Characteristics of Pachyonychia Congenita. 先天性毛囊角化症的发病率和患者特征。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.3727
Sara Rønde Andersen, Laura Krogh Herlin, Sigrun A J Schmidt, Mette Sommerlund
{"title":"Prevalence and Patient Characteristics of Pachyonychia Congenita.","authors":"Sara Rønde Andersen, Laura Krogh Herlin, Sigrun A J Schmidt, Mette Sommerlund","doi":"10.1001/jamadermatol.2024.3727","DOIUrl":"10.1001/jamadermatol.2024.3727","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1364-1366"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19. COVID-19 后自身免疫和自身炎症性结缔组织疾病的长期风险。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.4233
Yeon-Woo Heo, Jae Joon Jeon, Min Chul Ha, You Hyun Kim, Solam Lee

Importance: Few studies have investigated the association between COVID-19 and autoimmune and autoinflammatory connective tissue disorders; however, research with long-term observation remains insufficient.

Objective: To investigate the long-term risk of autoimmune and autoinflammatory diseases after COVID-19 over an extended observation period.

Design, setting, and participants: This retrospective nationwide population-based study investigated the Korea Disease Control and Prevention Agency-COVID-19-National Health Insurance Service (K-COV-N) cohort. Individuals with confirmed COVID-19 from October 8, 2020, to December 31, 2022, and controls identified among individuals who participated in the general health examination in 2018 were included in the analysis.

Exposures: Confirmed COVID-19.

Main outcomes and measures: Incidence and risk of autoimmune and autoinflammatory connective tissue disorders in patients after COVID-19. Various covariates, such as demographic characteristics, general health data, socioeconomic status, and comorbidity profiles, were balanced using inverse probability weighting.

Results: A total of 6 912 427 participants (53.6% male; mean [SD] age, 53.39 [20.13] years) consisting of 3 145 388 with COVID-19 and 3 767 039 controls with an observational period of more than 180 days were included. Alopecia areata (adjusted hazard ratio [AHR], 1.11 [95% CI, 1.07-1.15]), alopecia totalis (AHR, 1.24 [95% CI, 1.09-1.42]), vitiligo (AHR, 1.11 [95% CI, 1.04-1.19]), Behçet disease (AHR, 1.45 [95% CI, 1.20-1.74]), Crohn disease (AHR, 1.35 [95% CI, 1.14-1.60]), ulcerative colitis (AHR, 1.15 [95% CI, 1.04-1.28]), rheumatoid arthritis (AHR, 1.09 [95% CI, 1.06-1.12]), systemic lupus erythematosus (AHR, 1.14 [95% CI, 1.01-1.28]), Sjögren syndrome (AHR, 1.13 [95% CI, 1.03-1.25]), ankylosing spondylitis (AHR, 1.11 [95% CI, 1.02-1.20]), and bullous pemphigoid (AHR, 1.62 [95% CI, 1.07-2.45]) were associated with higher risk in the COVID-19 group. Subgroup analyses revealed that demographic factors, including male and female sex, age younger than 40 years, and age 40 years and older, exhibited diverse associations with the risk of autoimmune and autoinflammatory outcomes. In addition, severe COVID-19 infection requiring intensive care unit admission, the Delta period, and not being vaccinated were associated with higher risk.

Conclusions and relevance: This retrospective cohort study with an extended follow-up period found associations between COVID-19 and the long-term risk of various autoimmune and autoinflammatory connective tissue disorders. Long-term monitoring and care of patients is crucial after COVID-19, considering demographic factors, disease severity, and vaccination status, to mitigate these risks.

重要性:很少有研究调查了COVID-19与自身免疫性和自身炎症性结缔组织疾病之间的关联;然而,长期观察的研究仍然不足:调查长期观察 COVID-19 后患自身免疫性疾病和自身炎症性疾病的长期风险:这项以全国人口为基础的回顾性研究调查了韩国疾病预防控制机构-COVID-19-国民健康保险服务(K-COV-N)队列。分析对象包括 2020 年 10 月 8 日至 2022 年 12 月 31 日期间确诊为 COVID-19 的个体,以及在 2018 年参加一般健康检查的个体中确定的对照组:确诊的COVID-19.主要结果和测量指标:COVID-19后患者自身免疫性和自身炎症性结缔组织疾病的发病率和风险。采用反概率加权法平衡人口统计学特征、一般健康数据、社会经济状况和合并症概况等各种协变量:共纳入了 6 912 427 名参与者(53.6% 为男性;平均 [SD] 年龄为 53.39 [20.13] 岁),其中包括 3 145 388 名 COVID-19 患者和 3 767 039 名观察期超过 180 天的对照组患者。其中,斑秃(调整后危险比 [AHR],1.11 [95% CI,1.07-1.15])、全秃(AHR,1.24 [95% CI,1.09-1.42])、白癜风(AHR,1.11 [95% CI,1.04-1.19])、白塞氏病(AHR,1.45 [95% CI,1.20-1.74])、克罗恩病(AHR,1.35 [95% CI,1.14-1.60])、溃疡性结肠炎(AHR,1.15 [95% CI,1.04-1.28])、类风湿(AHR,1.15 [95% CI,1.04-1.19])。28])、类风湿性关节炎(AHR,1.09 [95% CI,1.06-1.12])、系统性红斑狼疮(AHR,1.14 [95% CI,1.01-1.28])、Sjögren 综合征(AHR,1.13 [95% CI,1.03-1.25])、强直性脊柱炎(AHR,1.15 [95% CI,1.04-1.28])。25])、强直性脊柱炎(AHR,1.11 [95% CI,1.02-1.20])和牛皮癣(AHR,1.62 [95% CI,1.07-2.45])与 COVID-19 组的较高风险相关。亚组分析显示,人口统计学因素(包括男女性别、40 岁以下和 40 岁及以上)与自身免疫和自身炎症结果的风险呈现出不同的关联。此外,需要入住重症监护室的严重COVID-19感染、德尔塔时期和未接种疫苗与较高风险相关:这项延长随访期的回顾性队列研究发现,COVID-19 与各种自身免疫性和自身炎症性结缔组织疾病的长期风险有关。考虑到人口统计学因素、疾病严重程度和疫苗接种情况,在 COVID-19 后对患者进行长期监测和护理对降低这些风险至关重要。
{"title":"Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19.","authors":"Yeon-Woo Heo, Jae Joon Jeon, Min Chul Ha, You Hyun Kim, Solam Lee","doi":"10.1001/jamadermatol.2024.4233","DOIUrl":"10.1001/jamadermatol.2024.4233","url":null,"abstract":"<p><strong>Importance: </strong>Few studies have investigated the association between COVID-19 and autoimmune and autoinflammatory connective tissue disorders; however, research with long-term observation remains insufficient.</p><p><strong>Objective: </strong>To investigate the long-term risk of autoimmune and autoinflammatory diseases after COVID-19 over an extended observation period.</p><p><strong>Design, setting, and participants: </strong>This retrospective nationwide population-based study investigated the Korea Disease Control and Prevention Agency-COVID-19-National Health Insurance Service (K-COV-N) cohort. Individuals with confirmed COVID-19 from October 8, 2020, to December 31, 2022, and controls identified among individuals who participated in the general health examination in 2018 were included in the analysis.</p><p><strong>Exposures: </strong>Confirmed COVID-19.</p><p><strong>Main outcomes and measures: </strong>Incidence and risk of autoimmune and autoinflammatory connective tissue disorders in patients after COVID-19. Various covariates, such as demographic characteristics, general health data, socioeconomic status, and comorbidity profiles, were balanced using inverse probability weighting.</p><p><strong>Results: </strong>A total of 6 912 427 participants (53.6% male; mean [SD] age, 53.39 [20.13] years) consisting of 3 145 388 with COVID-19 and 3 767 039 controls with an observational period of more than 180 days were included. Alopecia areata (adjusted hazard ratio [AHR], 1.11 [95% CI, 1.07-1.15]), alopecia totalis (AHR, 1.24 [95% CI, 1.09-1.42]), vitiligo (AHR, 1.11 [95% CI, 1.04-1.19]), Behçet disease (AHR, 1.45 [95% CI, 1.20-1.74]), Crohn disease (AHR, 1.35 [95% CI, 1.14-1.60]), ulcerative colitis (AHR, 1.15 [95% CI, 1.04-1.28]), rheumatoid arthritis (AHR, 1.09 [95% CI, 1.06-1.12]), systemic lupus erythematosus (AHR, 1.14 [95% CI, 1.01-1.28]), Sjögren syndrome (AHR, 1.13 [95% CI, 1.03-1.25]), ankylosing spondylitis (AHR, 1.11 [95% CI, 1.02-1.20]), and bullous pemphigoid (AHR, 1.62 [95% CI, 1.07-2.45]) were associated with higher risk in the COVID-19 group. Subgroup analyses revealed that demographic factors, including male and female sex, age younger than 40 years, and age 40 years and older, exhibited diverse associations with the risk of autoimmune and autoinflammatory outcomes. In addition, severe COVID-19 infection requiring intensive care unit admission, the Delta period, and not being vaccinated were associated with higher risk.</p><p><strong>Conclusions and relevance: </strong>This retrospective cohort study with an extended follow-up period found associations between COVID-19 and the long-term risk of various autoimmune and autoinflammatory connective tissue disorders. Long-term monitoring and care of patients is crucial after COVID-19, considering demographic factors, disease severity, and vaccination status, to mitigate these risks.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1278-1287"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11541739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipodermatosclerosis and Pulmonary Hypertension in Systemic Sclerosis. 系统性硬化症中的脂皮硬化症和肺动脉高压。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.3929
Srijana Davuluri, Puneet Kapoor, Swarna Nandyala, Shufeng Li, Julia Simard, Matthew Lewis, David Fiorentino, Lorinda Chung

Importance: Lipodermatosclerosis (LDS) stems from vascular dysfunction and dermal inflammation and thereby is mechanistically similar to systemic sclerosis (SSc). The association of LDS with SSc in the clinical setting has not been well characterized in the literature.

Objective: To evaluate the prevalence of LDS in SSc and the association of LDS with vascular complications, particularly pulmonary hypertension, in patients with SSc.

Design, setting, and participants: This retrospective cohort study used prospectively collected longitudinal data from a cohort of patients from the multidisciplinary rheumatology and dermatology clinic at a single tertiary care center from November 2004 to November 2022. Adult patients (aged ≥18 years at the time of cohort entry) with SSc were included.

Exposure: Clinical diagnosis of LDS based on expert opinion or histopathologic findings.

Main outcomes and measures: The main outcomes included prevalence of LDS, the association of LDS with the macrovascular complications, including pulmonary hypertension, digital gangrene and/or scleroderma renal crisis. Disease complications, including cardiac arrhythmias and heart failure, were compared among patients with and without LDS.

Results: Among 567 patients with SSc (494 [87.1%] female; mean [SD] age, 53.4 [14.4] years), 25 (4.4%) had LDS and 542 (95.6%) did not have LDS. Skin ulceration occurred in 8 patients with LDS (32.0%). Patients with LDS had higher frequencies of cardiac arrhythmia (11 of 24 [45.8%] vs 145 of 539 [26.9%]), heart failure (7 [28.0%] vs 55 [10.1%]), and pulmonary hypertension (12 [48.0%] vs 137 of 541 [25.3%]) compared with patients without LDS. Frequency of scleroderma renal crisis and digital gangrene did not differ significantly between patients with and without LDS (0 vs 37 [6.8%] and 4 [16.0%] vs 69 of 538 [12.8%], respectively). Among patients with LDS, 9 (36.0%) were either discharged to hospice or died during follow-up compared with 115 patients without LDS (21.2%). Lipodermatosclerosis was associated with pulmonary hypertension (adjusted prevalence odds ratio, 3.10; 95% CI, 1.33-7.25).

Conclusions and relevance: In this cohort study, LDS was a rare clinical manifestation in patients with SSc but was associated with pulmonary hypertension. Therefore, patients with LDS should be closely monitored and screened for pulmonary hypertension.

重要性:脂皮硬化症(LDS)源于血管功能障碍和真皮炎症,因此在机理上与系统性硬化症(SSc)相似。在临床环境中,LDS 与 SSc 的关联在文献中尚未得到很好的描述:评估 LDS 在 SSc 中的患病率,以及 LDS 与 SSc 患者血管并发症(尤其是肺动脉高压)的相关性:这项回顾性队列研究使用的是前瞻性收集的纵向数据,这些数据来自一家三级医疗中心多学科风湿病学和皮肤病学门诊的一组患者,时间跨度为 2004 年 11 月至 2022 年 11 月。研究纳入了成年 SSc 患者(进入队列时年龄≥18 岁):主要结果和测量指标:主要结果包括LDS患病率、LDS与肺动脉高压、数字坏疽和/或硬皮病肾危象等大血管并发症的相关性。对有和没有LDS的患者进行疾病并发症(包括心律失常和心力衰竭)比较:在567名SSc患者中(494人[87.1%]为女性;平均[SD]年龄为53.4[14.4]岁),25人(4.4%)患有LDS,542人(95.6%)未患LDS。8 名 LDS 患者(32.0%)出现了皮肤溃疡。与无 LDS 的患者相比,LDS 患者出现心律失常(24 例中的 11 例 [45.8%] vs 539 例中的 145 例 [26.9%])、心力衰竭(7 例 [28.0%] vs 55 例 [10.1%])和肺动脉高压(12 例 [48.0%] vs 541 例中的 137 例 [25.3%])的频率更高。硬皮病肾危象和数字坏疽的发生率在有 LDS 和没有 LDS 的患者之间没有显著差异(分别为 0 vs 37 [6.8%] 和 4 [16.0%] vs 538 人中的 69 [12.8%])。在患有 LDS 的患者中,有 9 人(36.0%)在随访期间出院或死亡,而没有 LDS 的患者有 115 人(21.2%)。脂质硬化症与肺动脉高压有关(调整后患病几率比3.10;95% CI,1.33-7.25):在这项队列研究中,LDS 在 SSc 患者中是一种罕见的临床表现,但与肺动脉高压有关。因此,LDS 患者应密切监测和筛查肺动脉高压。
{"title":"Lipodermatosclerosis and Pulmonary Hypertension in Systemic Sclerosis.","authors":"Srijana Davuluri, Puneet Kapoor, Swarna Nandyala, Shufeng Li, Julia Simard, Matthew Lewis, David Fiorentino, Lorinda Chung","doi":"10.1001/jamadermatol.2024.3929","DOIUrl":"10.1001/jamadermatol.2024.3929","url":null,"abstract":"<p><strong>Importance: </strong>Lipodermatosclerosis (LDS) stems from vascular dysfunction and dermal inflammation and thereby is mechanistically similar to systemic sclerosis (SSc). The association of LDS with SSc in the clinical setting has not been well characterized in the literature.</p><p><strong>Objective: </strong>To evaluate the prevalence of LDS in SSc and the association of LDS with vascular complications, particularly pulmonary hypertension, in patients with SSc.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study used prospectively collected longitudinal data from a cohort of patients from the multidisciplinary rheumatology and dermatology clinic at a single tertiary care center from November 2004 to November 2022. Adult patients (aged ≥18 years at the time of cohort entry) with SSc were included.</p><p><strong>Exposure: </strong>Clinical diagnosis of LDS based on expert opinion or histopathologic findings.</p><p><strong>Main outcomes and measures: </strong>The main outcomes included prevalence of LDS, the association of LDS with the macrovascular complications, including pulmonary hypertension, digital gangrene and/or scleroderma renal crisis. Disease complications, including cardiac arrhythmias and heart failure, were compared among patients with and without LDS.</p><p><strong>Results: </strong>Among 567 patients with SSc (494 [87.1%] female; mean [SD] age, 53.4 [14.4] years), 25 (4.4%) had LDS and 542 (95.6%) did not have LDS. Skin ulceration occurred in 8 patients with LDS (32.0%). Patients with LDS had higher frequencies of cardiac arrhythmia (11 of 24 [45.8%] vs 145 of 539 [26.9%]), heart failure (7 [28.0%] vs 55 [10.1%]), and pulmonary hypertension (12 [48.0%] vs 137 of 541 [25.3%]) compared with patients without LDS. Frequency of scleroderma renal crisis and digital gangrene did not differ significantly between patients with and without LDS (0 vs 37 [6.8%] and 4 [16.0%] vs 69 of 538 [12.8%], respectively). Among patients with LDS, 9 (36.0%) were either discharged to hospice or died during follow-up compared with 115 patients without LDS (21.2%). Lipodermatosclerosis was associated with pulmonary hypertension (adjusted prevalence odds ratio, 3.10; 95% CI, 1.33-7.25).</p><p><strong>Conclusions and relevance: </strong>In this cohort study, LDS was a rare clinical manifestation in patients with SSc but was associated with pulmonary hypertension. Therefore, patients with LDS should be closely monitored and screened for pulmonary hypertension.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1329-1333"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Axis Labels For Figures 1 and 2. 图 1 和图 2 轴标中的错误。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.4851
{"title":"Errors in Axis Labels For Figures 1 and 2.","authors":"","doi":"10.1001/jamadermatol.2024.4851","DOIUrl":"10.1001/jamadermatol.2024.4851","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1369"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence, In-Hospital and Long-Term Mortality, and Sequelae of Epidermal Necrolysis in Adults. 成人表皮坏死症的发病率、住院和长期死亡率及后遗症。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.3575
Thomas Bettuzzi, Bénédicte Lebrun-Vignes, Saskia Ingen-Housz-Oro, Emilie Sbidian

Importance: The incidence of epidermal necrolysis (EN), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), varies across studies. While in-hospital mortality rates range from 15% to 20%, contributors to long-term mortality have been rarely evaluated and remain unknown.

Objective: To assess the incidence of and compare factors associated with in-hospital mortality and postdischarge mortality and sequelae among patients with EN.

Design, setting, and participants: This cohort study used French Health System data from January 1, 2013, to December 31, 2022, and included all adult patients (aged ≥18 years) with EN identified using International Statistical Classification of Diseases, Tenth Revision codes combined with a validated algorithm.

Exposure: Epidermal necrolysis.

Main outcomes and measures: Incidence, in-hospital mortality, postdischarge mortality, and sequelae were assessed as main outcomes. Factors associated with mortality were assessed using a multivariable Cox proportional hazards model.

Results: A total of 1221 adult patients with EN (median [IQR] age, 66 [49-79] years; 688 females [56.3%]) were included. Incidence was 2.6 (95% CI, 2.5-2.7) cases per million person-years. The in-hospital mortality rate was 19% (95% CI, 17%-21%) and postdischarge mortality rate, 15% (95% CI, 13%-17%) for an overall mortality of 34% (95% CI, 31%-36%). In multivariable analysis, factors associated with in-hospital mortality were age (adjusted hazard ratio [AHR], 1.03 per year of age; 95% CI, 1.02-1.04 per year of age), history of cancer (AHR, 2.04; 95% CI, 1.53-2.72), dementia (AHR, 1.85; 95% CI, 1.12-3.07), liver disease (AHR, 1.81; 95% CI, 1.24-2.64), and EN severity (TEN vs SJS: AHR, 2.14; 95% CI, 1.49-3.07). Cancer, liver disease, and dementia remained associated with postdischarge mortality (AHR, 3.26 [95% CI, 2.35-4.53], 1.86 [95% CI, 1.11-3.13], and 1.95 [95% CI, 1.11-3.43], respectively). Conversely, EN initial severity was not associated with mortality after hospital discharge (TEN vs SJS: AHR, 0.95; 95% CI, 0.60-1.47), but acute complications remained associated (AHR, 2.14 [95% CI, 1.26-3.63] and 2.44 [95% CI, 1.42-4.18] for acute kidney injury and sepsis, respectively). The main sequelae were ophthalmologic and mood disorders.

Conclusion: The findings of this cohort study suggest that although EN is a rare condition, it is associated with high rates of in-hospital and postdischarge mortality among patients who are older and have comorbid conditions. However, in contrast with in-hospital mortality, postdischarge mortality is not associated with EN initial severity but with acute in-hospital complications (eg, acute kidney injury and sepsis). Future studies are needed to construct models to estimate long-term outcomes and sequelae in patients with EN.

重要性:表皮坏死症(EN),包括史蒂文斯-约翰逊综合征(SJS)和中毒性表皮坏死症(TEN)的发病率在不同研究中存在差异。虽然院内死亡率在 15% 到 20% 之间,但造成长期死亡率的因素却很少得到评估,至今仍不清楚:评估 EN 患者院内死亡率、出院后死亡率和后遗症的发生率,并比较与之相关的因素:这项队列研究使用了法国卫生系统从2013年1月1日至2022年12月31日的数据,纳入了所有使用《国际疾病统计分类第十版》代码并结合验证算法确定的EN成人患者(年龄≥18岁):主要结果和测量方法:评估发病率、院内死亡率、出院后死亡率和后遗症。采用多变量考克斯比例危险模型评估与死亡率相关的因素:共纳入了1221名耳鼻喉科成人患者(中位数[IQR]年龄为66[49-79]岁;688名女性[56.3%])。发病率为每百万人年 2.6 例(95% CI,2.5-2.7)。院内死亡率为 19%(95% CI,17%-21%),出院后死亡率为 15%(95% CI,13%-17%),总死亡率为 34%(95% CI,31%-36%)。在多变量分析中,与院内死亡率相关的因素有年龄(调整后危险比 [AHR],每岁 1.03;95% CI,每岁 1.02-1.04)、癌症病史(AHR,2.04;95% CI,1.53-2.72)、痴呆(AHR,1.85;95% CI,1.12-3.07)、肝病(AHR,1.81;95% CI,1.24-2.64)和 EN 严重程度(TEN vs SJS:AHR,2.14;95% CI,1.49-3.07)。癌症、肝病和痴呆症仍与出院后死亡率相关(AHR,分别为 3.26 [95% CI,2.35-4.53]、1.86 [95% CI,1.11-3.13] 和 1.95 [95% CI,1.11-3.43])。相反,EN 最初的严重程度与出院后的死亡率无关(TEN vs SJS:AHR,0.95;95% CI,0.60-1.47),但急性并发症仍然相关(急性肾损伤和败血症的 AHR 分别为 2.14 [95% CI,1.26-3.63] 和 2.44 [95% CI,1.42-4.18])。主要后遗症是眼科疾病和情绪障碍:这项队列研究的结果表明,虽然耳鼻喉科疾病是一种罕见疾病,但在年龄较大、合并症较多的患者中,耳鼻喉科疾病与较高的院内死亡率和出院后死亡率相关。然而,与院内死亡率相比,出院后死亡率与耳鼻喉科病最初的严重程度无关,而是与院内急性并发症(如急性肾损伤和败血症)有关。未来的研究需要构建模型,以估算EN患者的长期预后和后遗症。
{"title":"Incidence, In-Hospital and Long-Term Mortality, and Sequelae of Epidermal Necrolysis in Adults.","authors":"Thomas Bettuzzi, Bénédicte Lebrun-Vignes, Saskia Ingen-Housz-Oro, Emilie Sbidian","doi":"10.1001/jamadermatol.2024.3575","DOIUrl":"10.1001/jamadermatol.2024.3575","url":null,"abstract":"<p><strong>Importance: </strong>The incidence of epidermal necrolysis (EN), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), varies across studies. While in-hospital mortality rates range from 15% to 20%, contributors to long-term mortality have been rarely evaluated and remain unknown.</p><p><strong>Objective: </strong>To assess the incidence of and compare factors associated with in-hospital mortality and postdischarge mortality and sequelae among patients with EN.</p><p><strong>Design, setting, and participants: </strong>This cohort study used French Health System data from January 1, 2013, to December 31, 2022, and included all adult patients (aged ≥18 years) with EN identified using International Statistical Classification of Diseases, Tenth Revision codes combined with a validated algorithm.</p><p><strong>Exposure: </strong>Epidermal necrolysis.</p><p><strong>Main outcomes and measures: </strong>Incidence, in-hospital mortality, postdischarge mortality, and sequelae were assessed as main outcomes. Factors associated with mortality were assessed using a multivariable Cox proportional hazards model.</p><p><strong>Results: </strong>A total of 1221 adult patients with EN (median [IQR] age, 66 [49-79] years; 688 females [56.3%]) were included. Incidence was 2.6 (95% CI, 2.5-2.7) cases per million person-years. The in-hospital mortality rate was 19% (95% CI, 17%-21%) and postdischarge mortality rate, 15% (95% CI, 13%-17%) for an overall mortality of 34% (95% CI, 31%-36%). In multivariable analysis, factors associated with in-hospital mortality were age (adjusted hazard ratio [AHR], 1.03 per year of age; 95% CI, 1.02-1.04 per year of age), history of cancer (AHR, 2.04; 95% CI, 1.53-2.72), dementia (AHR, 1.85; 95% CI, 1.12-3.07), liver disease (AHR, 1.81; 95% CI, 1.24-2.64), and EN severity (TEN vs SJS: AHR, 2.14; 95% CI, 1.49-3.07). Cancer, liver disease, and dementia remained associated with postdischarge mortality (AHR, 3.26 [95% CI, 2.35-4.53], 1.86 [95% CI, 1.11-3.13], and 1.95 [95% CI, 1.11-3.43], respectively). Conversely, EN initial severity was not associated with mortality after hospital discharge (TEN vs SJS: AHR, 0.95; 95% CI, 0.60-1.47), but acute complications remained associated (AHR, 2.14 [95% CI, 1.26-3.63] and 2.44 [95% CI, 1.42-4.18] for acute kidney injury and sepsis, respectively). The main sequelae were ophthalmologic and mood disorders.</p><p><strong>Conclusion: </strong>The findings of this cohort study suggest that although EN is a rare condition, it is associated with high rates of in-hospital and postdischarge mortality among patients who are older and have comorbid conditions. However, in contrast with in-hospital mortality, postdischarge mortality is not associated with EN initial severity but with acute in-hospital complications (eg, acute kidney injury and sepsis). Future studies are needed to construct models to estimate long-term outcomes and sequelae in patients with EN.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1288-1296"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11447629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hidradenitis Suppurativa and Maternal and Offspring Outcomes. 化脓性扁桃体炎与母婴结局
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.3584
Kaiyang Li, Vincent Piguet, David Croitoru, Shu Qin Wei, Émilie Brousseau, Elizabeth O'Brien, Nathalie Auger

Importance: Hidradenitis suppurativa (HS) is associated with morbidity in persons of reproductive age, but the effect on maternal and offspring outcomes is understudied.

Objective: To determine the association of HS with pregnancy outcomes and maternal and child morbidity in the long term.

Design, setting, and participants: This population-based longitudinal cohort study with up to 16 years of follow-up took place between 2006 and 2022 in Quebec, Canada. .

Exposure: Maternal HS.

Main outcomes and measures: Outcomes included hypertensive disorders of pregnancy, gestational diabetes, and other birth outcomes as well as the long-term risk of hospitalization up to 16 years after delivery. The study used adjusted log-binomial and Cox proportional hazards regression models to estimate the association between maternal HS and pregnancy outcomes or hospitalization following pregnancy. Outcomes in both mothers and offspring were assessed.

Results: There were 1 324 488 deliveries during the study, including 1332 (0.1%) among mothers with HS. Compared with patients without HS, patients with HS had a greater risk of hypertensive disorders of pregnancy (risk ratio [RR], 1.55 [95% CI, 1.29-1.87]), gestational diabetes (RR, 1.61 [95% CI, 1.40-1.85]), and severe maternal morbidity (RR, 1.38 [95% CI, 1.03-1.84]). In neonates, maternal HS was associated with risk of preterm birth (RR, 1.28 [95% CI, 1.07-1.53]) and birth defects (RR, 1.29 [95% CI, 1.07-1.56]). In the long term, HS was associated with 2.29 times the risk of maternal hospitalization (95% CI, 2.07-2.55) and 1.31 times the risk of childhood hospitalization (95% CI, 1.18-1.45), including hospitalization for respiratory, metabolic, psychiatric, and immune-related morbidity over time.

Conclusions and relevance: This cohort study found that HS is associated with adverse maternal and offspring outcomes in the peripartum period and in the long term. Early detection and management of HS may help mitigate these outcomes.

重要性:化脓性扁桃体炎(HS)与育龄人群的发病率有关,但其对母婴结局的影响尚未得到充分研究:目的:确定HS与妊娠结局及母婴长期发病率的关系:这项以人口为基础的纵向队列研究于 2006 年至 2022 年在加拿大魁北克省进行,随访时间长达 16 年。.暴露:产妇高血压:结果包括妊娠高血压疾病、妊娠糖尿病、其他分娩结果以及产后 16 年内的长期住院风险。研究采用调整后的对数二项式和考克斯比例危险回归模型来估算母亲妊娠高血压与妊娠结局或妊娠后住院之间的关系。对母亲和后代的结果进行了评估:研究期间共有 1 324 488 例分娩,其中 1332 例(0.1%)的母亲患有 HS。与非 HS 患者相比,HS 患者发生妊娠高血压疾病(风险比 [RR],1.55 [95% CI,1.29-1.87])、妊娠糖尿病(RR,1.61 [95% CI,1.40-1.85])和严重孕产妇发病率(RR,1.38 [95% CI,1.03-1.84])的风险更高。在新生儿中,产妇 HS 与早产风险(RR,1.28 [95% CI,1.07-1.53])和出生缺陷(RR,1.29 [95% CI,1.07-1.56])相关。从长期来看,HS 与孕产妇住院风险的 2.29 倍(95% CI,2.07-2.55)和儿童住院风险的 1.31 倍(95% CI,1.18-1.45)相关,包括随着时间的推移因呼吸系统、代谢、精神和免疫相关疾病住院:这项队列研究发现,HS 与围产期和长期的不良母婴结局有关。早期发现和治疗 HS 可能有助于减轻这些后果。
{"title":"Hidradenitis Suppurativa and Maternal and Offspring Outcomes.","authors":"Kaiyang Li, Vincent Piguet, David Croitoru, Shu Qin Wei, Émilie Brousseau, Elizabeth O'Brien, Nathalie Auger","doi":"10.1001/jamadermatol.2024.3584","DOIUrl":"10.1001/jamadermatol.2024.3584","url":null,"abstract":"<p><strong>Importance: </strong>Hidradenitis suppurativa (HS) is associated with morbidity in persons of reproductive age, but the effect on maternal and offspring outcomes is understudied.</p><p><strong>Objective: </strong>To determine the association of HS with pregnancy outcomes and maternal and child morbidity in the long term.</p><p><strong>Design, setting, and participants: </strong>This population-based longitudinal cohort study with up to 16 years of follow-up took place between 2006 and 2022 in Quebec, Canada. .</p><p><strong>Exposure: </strong>Maternal HS.</p><p><strong>Main outcomes and measures: </strong>Outcomes included hypertensive disorders of pregnancy, gestational diabetes, and other birth outcomes as well as the long-term risk of hospitalization up to 16 years after delivery. The study used adjusted log-binomial and Cox proportional hazards regression models to estimate the association between maternal HS and pregnancy outcomes or hospitalization following pregnancy. Outcomes in both mothers and offspring were assessed.</p><p><strong>Results: </strong>There were 1 324 488 deliveries during the study, including 1332 (0.1%) among mothers with HS. Compared with patients without HS, patients with HS had a greater risk of hypertensive disorders of pregnancy (risk ratio [RR], 1.55 [95% CI, 1.29-1.87]), gestational diabetes (RR, 1.61 [95% CI, 1.40-1.85]), and severe maternal morbidity (RR, 1.38 [95% CI, 1.03-1.84]). In neonates, maternal HS was associated with risk of preterm birth (RR, 1.28 [95% CI, 1.07-1.53]) and birth defects (RR, 1.29 [95% CI, 1.07-1.56]). In the long term, HS was associated with 2.29 times the risk of maternal hospitalization (95% CI, 2.07-2.55) and 1.31 times the risk of childhood hospitalization (95% CI, 1.18-1.45), including hospitalization for respiratory, metabolic, psychiatric, and immune-related morbidity over time.</p><p><strong>Conclusions and relevance: </strong>This cohort study found that HS is associated with adverse maternal and offspring outcomes in the peripartum period and in the long term. Early detection and management of HS may help mitigate these outcomes.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1297-1303"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tralokinumab and Acitretin for the Treatment of Lamellar Ichthyosis. 特罗凯单抗和阿曲汀治疗片状鱼鳞病。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.3443
Axel De Greef, Marie Baeck
{"title":"Tralokinumab and Acitretin for the Treatment of Lamellar Ichthyosis.","authors":"Axel De Greef, Marie Baeck","doi":"10.1001/jamadermatol.2024.3443","DOIUrl":"10.1001/jamadermatol.2024.3443","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1366-1367"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Racial and Ethnic Differences in the Risk of Second Primary Melanoma. 二次原发性黑色素瘤风险的种族和民族差异。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.3450
Shoshana Zhang, Vishal R Patel, Jennifer C Spencer, Alex B Haynes, Adewole S Adamson
{"title":"Racial and Ethnic Differences in the Risk of Second Primary Melanoma.","authors":"Shoshana Zhang, Vishal R Patel, Jennifer C Spencer, Alex B Haynes, Adewole S Adamson","doi":"10.1001/jamadermatol.2024.3450","DOIUrl":"10.1001/jamadermatol.2024.3450","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1363-1364"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relative, Absolute, and Excess Risk of Second Primary Melanomas Among Multiple Racial and Ethnic Groups-Analysis of Rare Events. 多个种族和人种群体罹患第二原发性黑色素瘤的相对风险、绝对风险和超额风险--罕见事件分析。
IF 11.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-12-01 DOI: 10.1001/jamadermatol.2024.3551
Mya L Roberson, Ivo Abraham
{"title":"Relative, Absolute, and Excess Risk of Second Primary Melanomas Among Multiple Racial and Ethnic Groups-Analysis of Rare Events.","authors":"Mya L Roberson, Ivo Abraham","doi":"10.1001/jamadermatol.2024.3551","DOIUrl":"10.1001/jamadermatol.2024.3551","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":"1272"},"PeriodicalIF":11.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAMA dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1